D41/100

Is Erasca Inc (ERAS) a risky stock?

Sector: Biotechnology Price: $19.03 Composite: 41/100

As of July 27, 2026, Clavix grades Erasca Inc (ERAS) D for risk, a composite score of 41 out of 100 on an A+ to F scale, which puts ERAS in the "elevated risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.

Grade as of July 27, 2026. Clavix regrades every trading day.

ERAS price, last 3 months

ERAS's daily closes over the past three months. Clavix reads risk from the fundamentals and news behind the price, not the line itself.

$19.11 ▼ 11.1% · 3 months
Apr 24, 2026Jul 24, 2026

The five risk dimensions behind ERAS's grade

Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how ERAS scores on each, as of July 27, 2026.

Financial healthbalance sheet, margins, cash flow
56
News sentimentscored, sourced recent coverage
25
Macro exposuresensitivity to rates, dollar, oil
69
Sector resiliencestrength vs the broad market
91
Price stabilitydrawdown and volatility
13

What's moving ERAS's risk right now

Company-specific signals Clavix flags behind ERAS's current grade, drawn from recent news and filings as of July 27, 2026.

Regulatory · raising risk

Multiple law firms are notifying Erasca investors about a securities class action lawsuit. Investors who suffered losses have until August 10, 2026 to seek lead plaintiff status, and the lawsuit could mean legal costs and reputational damage for Erasca.

Recent ERAS news

The latest headlines Clavix ingested for Erasca Inc, newest first. These feed the news-sentiment dimension of ERAS's grade.

What a D grade means

On the Clavix A+ to F scale, ERAS's composite of 41 falls in the D band (35–49), read as "elevated risk." The scale is fixed, so the meaning never moves.

A+AA-B+BB-C+CC-D+DD-F
Get Clavix on iPhone → Or grade your whole portfolio free, no account needed.

This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell ERAS or any security. Grades are risk indicators, not predictions of return. Data may be delayed.